Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07198074 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
MinorTrial sites expanded: 255 → 259 locationsTrial sites expanded: 251 → 255 locationsv114Show 1 more changeShow less
Trial sites expanded: 251 → 255 locations
MinorStudy sites: 251 to 255v113
MinorTrial sites expanded: 245 → 251 locationsSite details revised at 1 of 251 sitesv112Show 1 more changeShow less
Site details revised at 1 of 251 sites
MinorStudy sites: 245 to 251v111
MinorStudy sites: 244 to 245v110
MinorStudy sites: 243 to 244v109
MinorSite contacts updated at 1 of 243 sitesv108
MinorStudy sites: 242 to 243v107
MinorSite details revised at 2 of 242 sitesv106
MinorTrial sites expanded: 232 → 242 locationsSite details revised at 1 of 242 sitesv105Show 1 more changeShow less
Site details revised at 1 of 242 sites
MinorSite details revised at 2 of 242 sitesv104
MinorStudy sites: 232 to 242v103
MinorSite details revised at 1 of 232 sitesv102
MinorStudy sites: 231 to 232v101
MinorStudy sites: 229 to 231v100
MinorTrial sites expanded: 223 → 228 locationsv99
MinorStudy sites: 223 to 228v98
MinorStudy sites: 222 to 223v97
MinorStudy sites: 221 to 222v96
MinorSite contacts updated at 2 of 221 sitesv95
MinorStudy sites: 220 to 221v94
MinorTrial sites expanded: 215 → 218 locationsv93
MinorTrial sites expanded: 212 → 215 locationsv92
MinorStudy sites: 212 to 215v91
MinorTrial sites expanded: 206 → 211 locationsv90
MinorStudy sites: 206 to 211v89
MinorTrial sites expanded: 203 → 206 locationsTrial sites expanded: 194 → 203 locationsv88Show 1 more changeShow less
Trial sites expanded: 194 → 203 locations
MinorStudy sites: 194 to 203v87
MinorStudy sites: 193 to 194v86
MinorStudy sites: 192 to 193v85
MinorStudy sites: 191 to 192v84
MinorStudy sites: 190 to 191v83
MinorStudy sites: 189 to 190v82
MinorStudy sites: 187 to 189v81
MinorStudy sites: 186 to 187v80
MinorStudy sites: 185 to 186v79
MinorStudy sites: 184 to 185v78
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adding bevacizumab to the combination of carboplatin, paclitaxel and pembrolizumab may be more effective than the usual treatment combinations of carboplatin and paclitaxel with or without pembrolizumab in treating patients with advanced or recurrent pMMR and TP53 mutated endometrial cancer.